PT - JOURNAL ARTICLE AU - Ramdial, P K AU - Naidoo, D K TI - Drug-induced cutaneous pathology AID - 10.1136/jcp.2008.058289 DP - 2009 Jun 01 TA - Journal of Clinical Pathology PG - 493--504 VI - 62 IP - 6 4099 - http://jcp.bmj.com/content/62/6/493.short 4100 - http://jcp.bmj.com/content/62/6/493.full SO - J Clin Pathol2009 Jun 01; 62 AB - Drug-induced cutaneous rashes, whether confined to the skin or part of a systemic disease, are characterised by a spectrum of inflammatory disease patterns that include perivascular dermatitis, nodular and diffuse dermatitis, vesiculobullous lesions, pustular eruptions, sclerodermoid reactions, vasculitis, folliculitis/perifolliculitis and panniculitis. While a single drug can elicit a range of reaction patterns, no reaction pattern is specific for a particular drug. Although the temporal link between initiation of drug therapy and the onset of the drug rash is critical to the diagnosis, drug reactions may also occur during the course of chronic drug ingestion. Clues to the drug-induced nature of the cutaneous eruption include the presence of overlapping histological reaction patterns and incongruent clinical and histopathological features. While eosinophils are an important tell-tale sign of a drug-induced reaction, they may also be conspicuous in skin rashes devoid of a drug association. Furthermore, eosinophils may be sparse or absent in some drug exanthems. Heightened awareness of the mimicry of a wide spectrum of cutaneous pathology by an ever-increasing range of therapeutic agents is pivotal to the diagnosis of drug-induced skin pathology.